uniQure Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure or view top-rated stocks.

8 brokers have issued twelve-month target prices for uniQure's stock. Their QURE stock forecasts range from $27.46 to $66.00. On average, they predict uniQure's stock price to reach $49.43 in the next twelve months. This suggests a possible upside of 158.7% from the stock's current price.
View analysts' price targets for uniQure or view top-rated stocks among Wall Street analysts.

uniQure's stock was trading at $20.74 at the start of the year. Since then, QURE shares have decreased by 7.9% and is now trading at $19.11.
View the best growth stocks for 2022 here.

uniQure is scheduled to release its next quarterly earnings announcement on Monday, July 25th 2022.
View our earnings forecast for uniQure.

uniQure (NASDAQ:QURE) posted its quarterly earnings data on Monday, May, 2nd. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.33. The biotechnology company earned $1.79 million during the quarter, compared to analysts' expectations of $51.23 million. uniQure had a net margin of 61.76% and a trailing twelve-month return on equity of 54.85%.
View uniQure's earnings history.

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

Some companies that are related to uniQure include Karuna Therapeutics (KRTX), Zai Lab (ZLAB), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), CureVac (CVAC), Indivior (INVVY), Pacira BioSciences (PCRX), Insmed (INSM), Corcept Therapeutics (CORT), Arvinas (ARVN) and ACADIA Pharmaceuticals (ACAD).
View all of QURE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

uniQure trades on the NASDAQ under the ticker symbol "QURE."

uniQure's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.36%), State Street Corp (6.03%), Vanguard Group Inc. (2.59%), JPMorgan Chase & Co. (1.90%), Bank of New York Mellon Corp (1.45%) and Federated Hermes Inc. (1.28%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Leonard E Post, Matthew C Kapusta, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Pierre Caloz, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends for uniQure.

QURE stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Federated Hermes Inc., Connor Clark & Lunn Investment Management Ltd., Bank of New York Mellon Corp, Henry James International Management Inc., Citigroup Inc., Jane Street Group LLC, and BNP Paribas Arbitrage SA. Company insiders that have sold uniQure company stock in the last two years include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Pierre Caloz, Ricardo Dolmetsch, and Robert Gut.
View insider buying and selling activity for uniQure or view top insider-selling stocks.

QURE stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Assenagon Asset Management S.A., JPMorgan Chase & Co., Acadian Asset Management LLC, BlackRock Inc., Integral Health Asset Management LLC, UBS Group AG, and Robeco Institutional Asset Management B.V..
View insider buying and selling activity for uniQure or or view top insider-buying stocks.

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QURE stock can currently be purchased for approximately $19.11.

uniQure (NASDAQ:QURE) has a market capitalization of $891.44 million and generates $524 million in revenue each year. The biotechnology company earns $329.59 million in net income (profit) each year or $6.89 on an earnings per share basis.

uniQure employs 463 workers across the globe.

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for uniQure is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at [email protected], or via fax at 31-20-566-9272.